

sicians can certainly have a role in reining in costs by declining to provide nonbeneficial interventions, far greater savings will be realized when patients themselves have some skin in the game.

Ami Laws, MD

Author Affiliations: Stanford University School of Medicine, Palo Alto, California (amilaws@earthlink.net).

Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

1. Brett AS, McCullough LB. Addressing requests by patients for nonbeneficial interventions. *JAMA*. 2012;307(2):149-150.

In Reply: We agree with Dr Cassel that new approaches that represent physician-led improvement in medical decision making may be beneficial for physicians and are consistent with the principles articulated in our essay.

Dr Laws raises 2 interesting points for consideration. First, to deter patients from making requests for inappropriate clinical management, she proposes that patients should have more financial skin in the game. This proposal has initial appeal for physicians because it would make things easier for physicians in selected cases: Patients would likely make fewer requests for inappropriate tests or treatments. On closer examination, however, there is serious ethical risk. When patients already have co-payments and deductibles that are high enough (and going higher) to dissuade them from seeking unnecessary care, they may also be dissuaded from seeking and implementing necessary medical care. This problem should not be exacerbated. The primary responsibility for managing the inappropriate requests from patients rests with physicians who should respectfully assert their professional integrity. This approach strikes a balance between providing effective medical care, respecting patients' preferences for reasonable interventions, and protecting patients from making bad decisions.

Second, we would define a modicum of benefit as a well-founded expectation of net clinical benefit, supported by evidence (when it exists) and by careful clinical reasoning. A reliable judgment about net clinical benefit requires the physician to identify expected or desired outcomes and the risks of intervention from a biopsychosocial perspective. Laws comments on our patient with low back pain; the question is whether an MRI can be expected to improve the treatment plan for the patient. The answer is unequivocally "no," given the clinical description of a healthy person with a few days of symptoms. The patient seeks the psychological benefit of reassurance that cancer is not present. The physician, thinking probabilistically, can anticipate that the likelihood of incidental findings (which have no bearing on the patient's symptoms, but which may well result in further worry for an already anxious person) far exceeds the near-zero probability of serious pathology. The "modicum of benefit" test is not met during this patient's initial clinical encounter. For the tiny subset of patients whose symptoms do not follow the expected course after a period of observation, the physician can initiate an appropriate evaluation without compromising long-term outcomes. The key here is the physician's commitment

to provide follow-up and willingness to revise probability estimates as symptoms unfold.

On rare occasions, performing a test solely to alleviate anxiety may be justified, but the physician needs to understand exactly what is making the patient anxious before assuming that testing will solve the problem. In most cases, spending time with the patient—educating, explaining, establishing trust, and providing reassurance—is more effective in conferring psychosocial benefit than an encounter in which the physician simply orders a drug or a test. This "path of least resistance" should be eschewed by physicians committed to protecting professional integrity in patient care.

Allan S. Brett, MD

Laurence B. McCullough, PhD

Author Affiliations: Department of Medicine, University of South Carolina School of Medicine, Columbia (Dr Brett) (abrett@sc.edu); Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas (Dr McCullough).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

RESEARCH LETTER

Dementia From Alzheimer Disease and Mixed Pathologies in the Oldest Old

To the Editor: The oldest old (≥ 90 years of age) are the fastest growing segment of the US population and account for half of all persons with dementia. Alzheimer disease (AD) is the most common pathology underlying dementia in the old (ages 65-89 years). Recent community-based autopsy studies^{1,2} suggest the relationship between AD pathology and expression of dementia is attenuated in the oldest old.³ Studies may be complicated by the common coexistence of AD plus infarct and/or Lewy body (LB) pathology (mixed pathologies).⁴ Few data exist on mixed pathologies and dementia in the oldest old.⁵ We examined the relationship of AD and mixed pathologies to dementia in the oldest old compared with the old. We tested the hypothesis that the clinical expression of AD and mixed pathologies differs across age groups.

Methods. We included 804 persons from the Religious Orders Study ($n=456$) and Rush Memory and Aging Project ($n=348$), ongoing longitudinal clinical-pathological studies of aging started in 1994 and 1997, respectively.⁴ Both were convenience samples of community-dwelling older adults with high follow-up ($>90\%$) and autopsy (87%) rates. All autopsied participants with complete data as of June 2, 2011 (93.7% of 858 autopsied) were included. Both studies were approved by the Rush University Medical Center institutional review board and all participants provided written consent.

Dementia was diagnosed using standard criteria (TABLE 1; last assessment: mean 7.1 months before death). Neuropathologic diagnoses were blinded to age and clinical diagnosis, using standard criteria (Table 1). Mixed pathologies included at least 2 of the following: a pathological diagnosis of AD, infarct (macroscopic or microscopic), or neocor-

cal LB (identified on α -synuclein immunostaining) pathology. We report prevalence ratios from log-binomial regression models controlling for sex and education with interaction terms for pathology by age group. Analyses were performed using SAS version 9.2 (SAS Institute Inc). Testing was 2-sided with statistical significance threshold of $\alpha = .05$.

Results. The oldest old ($n=301$; mean age=94.3 years) were more likely to be demented and to have pathological diagnoses of AD or infarct than the old ($n=503$; mean age=83.8 years) (Table 1). A pathological diagnosis of AD was associated with a higher prevalence of dementia in the old and the oldest old; however, the association was attenuated in the oldest old (model 1 in Table 2). In a model including pathological diagnoses of AD, infarct, and LB, all 3 pathologies were associated with dementia in the old and the oldest old, but only AD showed an interaction with age (model 2 in Table 2). Mixed but not single pathologies were more common in the oldest old, specifically AD plus infarct (Table 1). In both age groups, a pathological diagno-

sis of AD plus infarct and/or LB (mixed AD pathology) was associated with a higher prevalence ratio for dementia than a diagnosis of AD alone; however, the association of mixed AD pathologies with dementia was attenuated in the oldest old (model 3 in Table 2).

Comment. We found that a pathological diagnosis of AD was more common in the oldest old and strongly related to dementia. The increase in AD pathology in the oldest old was primarily in the form of mixed AD and infarct pathology, which was related to a higher probability of dementia than AD pathology alone. Thus, the proportional effect of AD pathology is high in the oldest old. Nonetheless, the relationship between a pathological diagnosis of AD and dementia was significantly attenuated in the oldest old compared with the old even after accounting for known mixed pathologies, suggesting additional factors in the pathogenesis of dementia in the oldest old.

Limitations include data from a volunteer cohort agreeable to autopsy and few minorities, which may limit generalizability. These data suggest that research on dementia

Table 1. Clinical and Pathological Characteristics at or Proximate to Death for Persons Younger Than 90 Years of Age at Death Compared With Persons Aged 90 Years or Older

Characteristic	Total (N = 804)	Age 65-89 (n = 503)	Age \geq 90 (n = 301)	P Value ^a
Age at death, mean (SD), y	87.7 (6.7)	83.8 (4.8)	94.3 (3.3)	<.001
Sex, No. (%)				
Male	296 (36.8)	213 (42.3)	83 (27.6)]. <.001
Female	508 (63.2)	290 (57.7)	218 (72.4)	
Education, mean (SD), y	16.5 (3.7)	16.7 (3.8)	16.2 (3.4)	.05
MMSE score, mean (SD) (range: 1-30)	21.9 (8.8)	23.5 (8.1)	19.2 (9.3)	<.001
Dementia, No. (%) ^b	304 (37.8)	143 (28.4)	161 (53.5)	<.001
Pathological type, No. (%)				
Any diagnosis ^c	599 (74.5)	351 (69.8)	248 (82.4)	<.001
AD ^d	493 (61.3)	279 (55.5)	214 (71.1)	<.001
LB (neocortical)	78 (9.7)	46 (9.2)	32 (10.6)	.49
Infarct ^e	272 (33.8)	147 (29.2)	125 (41.5)	<.001
Single pathologies	374 (46.5)	238 (47.3)	136 (45.2)	.56
AD (no infarct or LB)	271 (33.7)	167 (33.2)	104 (34.6)	.70
LB (no AD or infarct)	15 (1.9)	12 (2.4)	3 (1.0)	.16
Infarct (no AD or LB)	88 (11.0)	59 (11.7)	29 (9.6)	.36
Mixed pathologies	225 (28.0)	113 (22.5)	112 (37.2)	<.001
AD plus LB	41 (5.1)	25 (5.0)	16 (5.3)	.83
AD plus infarct	162 (20.2)	79 (15.7)	83 (27.6)	<.001
LB plus infarct	3 (0.4)	1 (0.2)	2 (0.7)	.29
AD plus LB plus infarct	19 (2.4)	8 (1.6)	11 (3.7)	.06

Abbreviations: AD, Alzheimer disease; LB, Lewy body; MMSE, Mini-Mental State Examination.

^aCalculated from χ^2 tests or *t* test.

^bDiagnosed using the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders criteria (McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer Disease. *Neurology*. 1984;34[7]:939-944). Of participants with dementia, 18 (12.6%) aged 65 to 89 years and 21 (13.0%) aged 90 years or older had no pathological diagnosis of Alzheimer disease; 9 (6.3%) aged 65 to 89 and 9 (5.6%) aged 90 years or older had none of the pathological diagnoses examined (Alzheimer disease, LB, or infarct pathology).

^cIncludes diagnosis of AD, LB, or infarct pathology.

^dA modified Bielschowsky silver stain was used to visualize neuritic plaques and neurofibrillary tangles in the frontal, temporal, parietal, entorhinal, and hippocampal cortices. Neuropathologic diagnoses were made by a board-certified neuropathologist blinded to age and clinical diagnosis. The neuropathologic diagnosis of AD was made using the National Institutes of Aging-Reagan criteria (intermediate or high likelihood) without adjustment for age or clinical diagnosis (National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer disease. *Neurobiol Aging*. 1997;18[4 suppl]:S1-S2).

^eIncluded all confirmed chronic macroscopic infarcts and chronic cortical microscopic infarcts.

Table 2. Prevalence of Clinical Dementia Associated With Alzheimer Disease Pathology Alone and Mixed Pathologies

Pathological Diagnosis	Prevalence of Dementia	Prevalence Ratio (95% CI)	
		Alone ^a	Interaction ^b
Model 1^c			
No AD			
Age 65-89 y	0.08	1 [Reference]	
Age ≥90 y	0.24	2.99 (1.67-5.33)	
AD			
Age 65-89 y	0.45	5.57 (3.51,8.84)	
Age ≥90 y	0.66	8.08 (5.13-12.74)	0.49 (0.27-0.89)
Model 2^d			
No AD, infarct, or LB			
Age 65-89 y	0.07	1 [Reference]	
Age ≥90 y	0.23	3.11 (1.72-5.60)	
AD			
Age 65-89 y	0.39	5.23 (3.29-8.32)	
Age ≥90 y	0.59	7.95 (4.94-12.77)	0.49 (0.27-0.90)
LB			
Age 65-89 y	0.12	1.67 (1.29-2.16)	
Age ≥90 y	0.31	4.12 (2.22-7.65)	0.80 (0.57-1.12)
Infarct			
Age 65-89 y	0.10	1.28 (1.01-1.63)	
Age ≥90 y	0.27	3.60 (1.99-6.52)	0.91 (0.67-1.23)
Model 3^e			
No AD			
Age 65-89 y	0.08	1 [Reference]	
Age ≥90 y	0.24	2.99 (1.67-5.33)	
AD			
Age 65-89 y	0.37	4.47 (2.75-7.27)	
Age ≥90 y	0.58	7.12 (2.98-17.00)	0.53 (0.28-1.01)
AD, infarct, or LB			
Age 65-89 y	0.59	7.22 (4.51-11.55)	
Age ≥90 y	0.73	8.98 (3.79-21.26)	0.42 (0.23-0.77)

Abbreviations: AD, Alzheimer disease; LB, Lewy body.

^aResults are from log-binomial regression models and are adjusted for sex and education.

^bCalculated as pathology type × age of 90 years or older. A value below 1 indicates the increase in prevalence for that pathology type is attenuated in the oldest old (age ≥90 years).

^cIncludes terms for age (≥90 years), AD pathology, and interactions of age (≥90 years) with AD.

^dEverything in footnote ^c plus LB pathology, infarct pathology, and the interactions of age (≥90 years) with AD, LB, and infarct pathologies.

^eIncludes terms for age (≥90 years), AD pathology only, mixed AD pathologies (AD plus infarct, AD plus LB, or AD plus infarct plus LB), and the interactions of age (≥90 years) with AD only and age (≥90 years) with mixed AD pathologies.

in the oldest old should focus on AD, mixed pathologies, and exploration of additional factors in the pathogenesis of dementia in the oldest old.

Bryan D. James, PhD
David A. Bennett, MD
Patricia A. Boyle, PhD
Sue Leurgans, PhD
Julie A. Schneider, MD

Author Affiliations: Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois (bryan_james@rush.edu).

Author Contributions: Dr James had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: James, Bennett, Schneider.

Acquisition of data: Bennett, Schneider.

Analysis and interpretation of data: James, Bennett, Boyle, Leurgans, Schneider.

Drafting of the manuscript: James, Schneider.

Critical revision of the manuscript for important intellectual content: James, Bennett, Boyle, Leurgans, Schneider.

Statistical analysis: James, Bennett, Leurgans, Schneider.

Obtained funding: Bennett, Boyle.

Administrative, technical, or material support: Bennett.

Study supervision: Bennett, Schneider.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr James reported serving as a consultant to the Alzheimer's Association and Partners. Dr Schneider reported being a consultant to AVID Radiopharmaceuticals Inc, GE Healthcare, and Eli Lilly. No other author reported disclosures.

Funding/Support: This research was supported by National Institute on Aging grants P30AG10161, R01AG15819, R01AG17917, R01AG34374, R01AG33678, RC2AG36547, P01AG14449, P01AG09466, and R01NS028127, and the Illinois Department of Public Health.

Role of the Sponsors: National Institute on Aging and the Illinois Department of Public Health had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

1. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C; Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. *N Engl J Med.* 2009;360(22):2302-2309.

2. Haroutunian V, Schnaider-Beeri M, Schmeidler J, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. *Arch Neurol.* 2008; 65(9):1211-1217.

3. Imhof A, Kövari E, von Gunten A, et al. Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? *J Neurol Sci.* 2007; 257(1-2):72-79.

4. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology.* 2007;69(24):2197-2204.

5. Middleton LE, Grinberg LT, Miller B, Kawas C, Yaffe K. Neuropathologic features associated with Alzheimer disease diagnosis: age matters. *Neurology.* 2011; 77(19):1737-1744.